COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08QLM
|
|||
| Drug Name |
Merimepodib
|
|||
| Synonyms |
Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) | Investigative | [1] | |
| Other Indication | Hepatitis C virus infection | Phase 2b | [2] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Company |
GSK
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H24N4O6
|
|||
| Canonical SMILES |
COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)OC3CCOC3)C4=CN=CO4
|
|||
| InChI |
1S/C23H24N4O6/c1-30-20-10-17(5-6-19(20)21-12-24-14-32-21)27-22(28)26-16-4-2-3-15(9-16)11-25-23(29)33-18-7-8-31-13-18/h2-6,9-10,12,14,18H,7-8,11,13H2,1H3,(H,25,29)(H2,26,27,28)/t18-/m0/s1
|
|||
| InChIKey |
JBPUGFODGPKTDW-SFHVURJKSA-N
|
|||
| CAS Number |
CAS 198821-22-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
640687, 10251736, 12015083, 14784233, 14857722, 46229554, 47206686, 52470262, 57347884, 103261008, 103998789, 104435748, 128251684, 134223085, 134338650, 134340678, 135110565, 137237685, 137267687, 141966212, 163306660, 175426334, 175426871, 179150134, 184528635, 198954413, 210275043, 210280681, 224157104, 226666702, 242060097, 252479539
|
|||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) | Target Info | Inhibitor | [1] |
| Merimepodib can inhibit SARS-CoV-2 replication at low concentrations due to its inhibition of IMPDH, leading to a depletion of guanosine for use by the viral polymerase during replication. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro. April 09, 2020. doi: https://doi.org/10.1101/2020.04.07.028589 | |||
| 2 | Merimepodib, Pegylated Interferon, and Ribavirin in Genotype 1 Chronic Hepatitis C Pegylated Interferon and Ribavirin Nonresponders. Hepatology. 2009 Dec;50(6):1719-26. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.